SANT-2
SANT-2 is a small-molecule antagonist of the sonic hedgehog pathway, a developmental signaling cascade implicated in tissue patterning, stem cell maintenance, and the progression of various cancers. By targeting the smoothened receptor, SANT-2 disrupts aberrant Shh pathway activation, thereby inhibiting downstream transcriptional programs that drive uncontrolled cell proliferation and survival. Due to its potency and specificity, SANT-2 has become a tool for studying Hedgehog-dependent oncogenesis and holds potential as a lead compound for the development of targeted anticancer therapeutics.
Pharmacology
SANT-2 is a potent antagonist of the Smoothened receptor, a key component of the Sonic hedgehog signaling pathway, displaying a dissociation constant of 12 nM for SMO binding. Its pharmacological profile is characterized by strong allosteric binding—similar to the first-in-class SMO antagonist SANT-1, interfering with the receptor’s activity even in the presence of endogenous and synthetic agonists. SANT-2 efficiently displaces radiolabeled SAG-1.3 and cyclopamine bound to SMO, with inhibition constants of 7.8 nM and 8.4 nM, respectively, highlighting its high affinity and specificity for this receptor.
Synthesis
SANT-2 is synthesized by coupling 2-chloro-5-nitrobenzoic acid with o-phenylenediamine to form a benzimidazole intermediate. Béchamp reduction of the nitro group affords the corresponding aniline, which is then coupled with 3,4,5-triethoxybenzoic acid via amide formation to yield SANT-2.